Company Overview and News
Buru Energy Ltd (ASX:BRU) is able to use the Ungani access road with light vehicles as water levels have generally receded below the roadbed level.
Carbon pollution from fracking all Western Australia’s potential unconventional gas reserves would blow Australia’s entire carbon budget under the Paris Agreement three times over, new research shows.
The amount of land "disturbed" by mining companies in Western Australia over 2016 and 2017 is roughly equivalent to the size of Hong Kong, new figures have revealed.
Buru Energy Ltd (ASX:BRU) is back to producing oil and generating revenue from its wholly-owned Ungani Oilfield in Western Australia, following a cyclone event.
Buru Energy Ltd (ASX:BRU) is now preparing to reveal data from the production tests at Ungani 5, located within its wholly-owned Ungani Oilfield in Western Australia.
Buru Energy Ltd (ASX:BRU) has received a positive re-rating from the market as the company has started monetising resources through the sale of oil from its wholly-owned Ungani Oilfield in the Canning Basin of Western Australia.
Buru Energy Ltd (ASX:BRU) is more than doubling oil handling capacity to 4,900 barrels a day at its wholly owned Ungani Oilfield in the Canning Basin of Western Australia.
WA conservation groups say the State Government's decision to axe an agreement with fracking companies in the state's north-west could be the catalyst for an "east coast-to-west coast gas pipeline."
The state government has moved to terminate a state agreement with Mitsubishi Corporation and Buru Energy that was enacted in 2013 when there were high hopes that fracking in the Kimberley’s Canning Basin would lead to development of major onshore gas projects.
Buru Energy's (ASX:BRU), Executive Chairman Eric Streitberg tells us about the big year behind and the big year ahead after a capital raising exercise, a new drilling programme and increased oil production. Hear how Buru's solid focus on exploring as well as production has been critical to planning Buru's prospects for 2018 and how this year's major portfolio restructuring has now paid off.
Buru Energy Limited (ASX:BRU) continues to deliver for its shareholders regarding development and production from its 100% owned Ungani Oilfield, located in the Canning Basin of Western Australia.
2018-04-25 - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
2018-04-25 - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...